Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study

Journal of Cardiovascular Electrophysiology

Volumn 27, Issue 5, 2016, Pages 549-554

  Kuwahara, Taishi ^a   Abe, Mitsunori ^b   Yamaki, Masaru ^c   Fujieda, Hiroyuki ^b   Abe, Yumiko ^b   Hashimoto, Katsushi ^b   Ishiba, Misako ^c   Sakai, Hirotsuka ^c   Hishikari, Keiichi ^a   Takigawa, Masateru ^a   Okubo, Kenji ^a   Takagi, Katsumasa ^a   Tanaka, Yasuaki ^a   Nakajima, Jun ^a   Takahashi, Atsushi ^a  

^a YOKOSUKA KYOSAI HOSPITAL   (Japan)

^b Yotsuba Circulation Clinic   (Japan)

^c Nayoro City General Hospital   (Japan)

Author keywords

anticoagulant; apixaban; atrial fibrillation; catheter ablation; silent cerebral infarction; stroke; warfarin

Indexed keywords

APIXABAN; BRAIN NATRIURETIC PEPTIDE; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABLATION CATHETER; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; BRAIN INFARCTION; CATHETER ABLATION; CEREBRAL THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; DIAPHRAGM PARALYSIS; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW RATE; GROIN HEMATOMA; HEART ATRIUM APPENDAGE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TAMPONADE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SCANNER; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SILENT CEREBRAL INFARCTION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; BLEEDING; BLOOD CLOTTING; BRAIN ISCHEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG MONITORING; INTRACRANIAL EMBOLISM; INTRACRANIAL THROMBOSIS; JAPAN; MIDDLE AGED; PROCEDURES; RISK FACTOR; STROKE; TIME FACTOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BRAIN ISCHEMIA; CATHETER ABLATION; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG MONITORING; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL EMBOLISM; INTRACRANIAL THROMBOSIS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; WARFARIN;

EID: 84975784460     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12928     Document Type: Article

References (32)

1. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E,: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
2. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, Klein G, Natale A, Packer D, Skanes A,: Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53: 1798-1803.
3. Lickfett L, Hackenbroch M, Lewalter T, Selbach S, Schwab JO, Yang A, Balta O, Schrickel J, Bitzen A, Lüderitz B, Sommer T,: Cerebral diffusion-weighted magnetic resonance imaging: A tool to monitor the thrombogenicity of left atrial catheter ablation. J Cardiovasc Electrophysiol 2006; 17: 1-7.
4. Gaita F, Caponi D, Pianelli M, Scaglione M, Toso E, Cesarani F, Boffano C, Gandini G, Valentini MC, De Ponti R, Halimi F, Leclercq JF,: Radiofrequency catheter ablation of atrial fibrillation: A cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122: 1667-1673.
5. Schrickel JW, Lickfett L, Lewalter T, Mittman-Braun E, Selbach S, Strach K, Nähle CP, Schwab JO, Linhart M, Andrié R, Nickenig G, Sommer T,: Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010; 12: 52-57.
6. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, Schade A, Froehner S, Ziegler V, Sergi D, Cesarani F, Blandino A,: Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: Comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 2011; 22: 961-968.
7. Herrera Siklódy C, Deneke T, Hocini M, Lehrmann H, Shin D-I, Miyazaki S, Henschke S, Fluegel P, Schiebeling-Römer J, Bansmann PM, Bourdias T, Dousset V, Haïssaguerre M, Arentz T,: Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: Comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol 2011; 58: 681-688.
8. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A,: Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644.
9. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, Hongo R, Beheiry S, Bai R, Mohanty P, Lewis WR, Natale A,: Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5: 302-311.
10. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L,; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
11. Kuwahara T, Takahashi A, Kobori A, Miyazaki S, Takahashi Y, Takei A, Nozato T, Hikita H, Sato A, Aonuma K,: Safe and effective ablation of atrial fibrillation: Importance of esophageal temperature monitoring to avoid periesophageal nerve injury as a complication of pulmonary vein isolation. J Cardiovasc Electrophysiol 2009; 20: 1-6.
12. Kuwahara T, Takahashi A, Takahashi Y, Kobori A, Miyazaki S, Takei A, Fujino T, Okubo K, Takagi K, Fujii A, Takigawa M, Watari Y, Hikita H, Sato A, Aonuma K,: Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration. J Cardiovasc Electrophysiol 2013; 24: 510-515.
13. Schulman S, Kearon C,; the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of The International Society on Thrombosis and Haemostasis: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
14. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, Yamamoto T, Yoshida N, Hirai M, Murohara T,: Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol 2015; 38: 155-163.
15. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, Mohanty P, Prakash S, Bai R, Reddy M, Gianni C, Horton R, Bailey S, Sigmund E, Derndorfer M, Schade A, Mueller P, Szoelloes A, Sanchez J, Al-Ahmad A, Hranitzky P, Gallinghouse GJ, Hongo RH, Beheiry S, Pürerfellner H, Burkhardt JD, Natale A,: Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm 2015; 12: 1162-1168.
16. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, Martin DO, Kanj M, Arruda M, Cummings J, Schweikert R, Saliba W, Natale A,: Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
17. Garton AB, Dudzinski J, Kowey PR,: Oral anticoagulant use around the time of atrial fibrillation ablation: A review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. J Cardiovasc Electrophysiol 2014; 25: 1411-1418.
18. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, Gunter A, McElderry HT,: Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24: 861-865.
19. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE, Garbati MA, Bahmaid RA, Wimmer AP,: Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Europace 2013; 15: 1412-1420.
20. Hohnloser SH, Camm AJ,: Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature. Europace 2013; 15: 1407-1411.
21. Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, Lashevsky I, Healey JS, Crystal E,: Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: A meta-analysis. Can J Cardiol 2013; 29: 1203-1210.
22. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, Piccini JP,: Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: A meta-analysis of observational studies. J Interv Card Electrophysiol 2013; 37: 213-221.
23. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS,: Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 2014; 113: 1173-1177.
24. Phan K, Wang N, Pison L, Kumar N, Hitos K, Thomas SP,: Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation. Int J Cardiol 2015; 189: 199-203.
25. Rillig A, Lin T, Plesman J, Heeger C-H, Lemes C, Metzner A, Mathew S, Wissner E, Wohlmuth P, Ouyang F, Kuck K-H, Tilz RR,: Apixaban, rivaroxaban and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 2015; 27: 147-153.
26. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma C-S, Hess S, Wells DS, Juang G, Vijgen J, Hügl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A,; VENTURE-AF Investigators: Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-1811.
27. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D,: Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos Biol Fate Chem 2009; 37: 74-81.
28. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U,: A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
29. Guerra JM, Jorge E, Raga S, Gálvez-Montón C, Alonso-Martín C, Rodríguez-Font E, Cinca J, Viñolas X,: Effects of open-irrigated radiofrequency ablation catheter design on lesion formation and complications: In vitro comparison of 6 different devices. J Cardiovasc Electrophysiol 2013; 24: 1157-1162.
30. Bin Abdulhak AA, Kennedy KF, Gupta S, Giocondo M, Ramza B, Wimmer AP,: Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: A prospective observational study. J Interv Card Electrophysiol 2015; 44: 91-96.
31. Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S, Mizutani Y, Ito T, Yamamoto T, Yoshida N, Hirai M, Murohara T,: Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm 2015; 12: 1972-1978.
32. Schlaug G, Siewert B, Benfield A, Edelman RR, Warach S,: Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology 1997; 49: 113-119.